Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02176317 · ClinicalTrials.gov registry record · Phase 1

Autologous Umbilical Cord Blood Infusion for Children With Autism Spectrum Disorder (ASD)

A Phase 1 study of Autism Spectrum Disorder, sponsored by Duke University.

Completed
Registry status
Phase 1
Development phase
25
Enrollment target
1
Study location

NCT02176317: Completed Phase 1 study of Autism Spectrum Disorder, sponsored by Duke University.

NCT02176317 is a Phase 1 study of Autism Spectrum Disorder that has completed, run by Duke University. The registered enrollment target is 25 participants, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02176317, a Phase 1 study of Autism Spectrum Disorder, has completed, sponsored by Duke University.

COMPLETED
Registry status
Phase 1
Development phase
25 participants
Enrollment target
1
Study location

Study Summary

This study is a prospective phase 1 single-center trial designed to determine the safety of a single intravenous infusion of autologous umbilical cord blood in children with Autism Spectrum Disorder (ASD) and assess the feasibility of various outcome measures to determine which measure(s) can be used as primary and secondary endpoints for a future randomized phase 2 clinical trial. All subjects will receive infusion of cord blood cells at baseline with follow up assessments at 6 and 12 months.

Conditions Studied

Interventions

  • BIOLOGICAL Autologous Umbilical Cord Blood

Study Locations (1)

North Carolina

  • Duke University Medical Center - Durham

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2014-06
Est. Completion 2015-12
Phase Phase 1
Duke University

1,725 total trials

What the finished NCT02176317 record still lists

NCT02176317 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (81% lower).

The record links to 1 condition, with Autism Spectrum Disorder appearing as the primary indexed condition, and to 1 intervention - of which Autologous Umbilical Cord Blood is the first listed.

NCT02176317 reports a single indexed study location in North Carolina.

Frequently Asked Questions

What is clinical trial NCT02176317 about?

NCT02176317 is a clinical study titled "Autologous Umbilical Cord Blood Infusion for Children With Autism Spectrum Disorder (ASD)". This study is a prospective phase 1 single-center trial designed to determine the safety of a single intravenous infusion of autologous umbilical cord blood in children with Autism Spectrum Disorder (ASD) and assess the feasibility of various outcome measures to determine which measure(s) can be use...

What is the current status of trial NCT02176317?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2014-06. Estimated completion is 2015-12.

What conditions does trial NCT02176317 study?

This clinical trial studies the following conditions: Autism Spectrum Disorder.

What interventions are being tested in trial NCT02176317?

The interventions under investigation include: Autologous Umbilical Cord Blood (BIOLOGICAL).

Who is sponsoring clinical trial NCT02176317?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02176317 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Autism Spectrum Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02176317's enrollment target sits among peer trials

25 183rd of 224 higher than 38 of 224 other Autism Spectrum Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Autism Spectrum Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01166854 · 25 participants

    Characterization of Familial Myopathy and Paget Disease of Bone

  • NCT01913106 · 25 participants · Phase 1

    HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer

  • NCT02138669 · 25 participants · NA

    Intacs Prescription Inserts for Keratoconus Patients

  • NCT02174549 · 25 participants · Phase 1

    Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02176317, the US trial registry maintained by the National Library of Medicine. NCT02176317 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.